40.00
-0.0399(-0.10%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
222
First IPO Date
June 05, 2020
| Name | Title | Pay | Year Born |
| Ms. Renee Aguiar-Lucander | Chief Executive Officer | 11.72M | 1962 |
| Mr. Fredrik Johansson | Chief Financial Officer | 0 | 1977 |
| Lars Stubberud | Vice President of Technical Operations | 0 | 1964 |
| Ms. Asa Hillsten | Head of IR & Sustainability | 0 | 1975 |
| Mr. Brian Gorman | Group General Counsel | 0 | 1976 |
| Ms. Sandra Frithiof | Vice President of Human Resources | 0 | 1975 |
| Ms. Ann-Kristin Myde BSc | Head of Clinical Development & Vice President of Project Management | 0 | 1955 |
| Dr. Richard S. Philipson M.D. | Chief Medical Officer | 0 | 1964 |
| Ms. Teona Johnson | Head of US Marketing | 0 | N/A |
| Mr. David Ferraro | Head of US Sales | 0 | N/A |
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.